Alcolase, a Denmark-based biotech company, has raised $1.7 million led by Ada Ventures to develop the world's first enzyme-based supplement that breaks down toxic acetaldehyde from alcohol in the stomach before it enters the bloodstream. The product enables people with genetic alcohol intolerance to drink socially without symptoms such as flushing, nausea or rapid heartbeat. The capital will fund clinical studies, intellectual property filings and an initial launch in Singapore.
Enzyme Supplements Target Intolerance Market
The timing aligns with rising interest in functional supplements for metabolic health. ZBiotics raised over $12 million to develop a probiotic that breaks down acetaldehyde after alcohol enters the bloodstream. Alcolase instead prevents absorption upfront in the stomach, addressing a specific genetic deficiency that affects hundreds of millions.
ALDH2 Deficiency Affects 540 Million
Approximately 540 million people globally suffer from ALDH2 deficiency, concentrated in East Asia, leaving them unable to metabolize alcohol efficiently. Current options offer no cure and force complete avoidance or painful symptoms. No targeted enzyme solution existed until Alcolase's stomach-delivery technology using liposomal encapsulation to survive stomach acid.
Pre-Bloodstream Breakdown Differentiates Product
Alcolase's enzyme system acts before alcohol reaches the blood, reducing both immediate symptoms and longer-term cancer risks tied to acetaldehyde buildup. This differs from competitors like Cheers, which focus on post-consumption hangover relief through DHM and L-cysteine, or NoHang's herbal blends. The approach draws from lactose intolerance enzyme models but applies them to alcohol metabolism.
"We want to give people a real choice they are currently denied." – Mikkel Precht, CEO
European-Asian Syndicate Backs Launch
Ada Ventures led the round with support from Delphinus Venture Capital, Antler and Manigoff Invest. The syndicate combines European life-sciences expertise with Asian market access, directly supporting plans for Singapore entry followed by South Korea. Earlier angel backing from Jesper Lomborg Manigoff laid groundwork for the institutional round.
Digestive Enzyme Market Grows Steadily
The digestive enzyme supplements market stood at $1.48 billion in 2024 and is projected to reach $2.12 billion by 2030 at a 6.2% CAGR. Broader trends show declining alcohol consumption alongside demand for harm-reduction products. GLP-1 drugs like semaglutide have further spotlighted pharmacological tools for moderating alcohol intake.
Singapore Entry Signals Asia Focus
With the new funding, Alcolase will advance regulatory preparations and studies while establishing commercial presence in Singapore. The company has also appointed Henrik Almblad as CSO to strengthen scientific development ahead of market entry. International pitching at events in Brussels and TechBBQ underscores expansion momentum.